EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan

Hiroshi Tada, Minoru Miyashita, Narumi Harada-Shoji, Akiko Ebata, Miku Sato, Tokiwa Motonari, Mika Yanagaki, Tomomi Kon, Aru Sakamoto, Takanori Ishida

Breast Cancer · 2025

DOI: 10.1007/s12282-024-01639-6 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Breast Cancer, 2025. Verfasst von Hiroshi Tada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-…. Hauptthemen laut MEDLINE: Breast Neoplasms, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This rapid communication highlights the correlation between protein kinase B alpha ( AKT1 )-phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA )- phosphatase and tensin homolog ( PTEN ) alterations and clinicopathological factors in Japanese patients with metastatic recurrent breast cancer (mBC). This study analyzed 1967 patients with luminal-type breast cancer who underwent cancer gene panel testing. The results demonstrated that AKT pathway alterations, including PI3K/AKT/PTEN , occurred in 1038 (52.8%) cases. Patients with AKT pathway mutations were older (p = 0.002) and had a higher rate of invasive lobular carcinoma (ILC) histology (p = 0.001), progesterone receptor (PgR) positivity (p = 0.006), and bone metastases (p = 0.001), and a lower rate of germline BRCA2 (p < 0.001). Comprehensive genomic profile results demonstrated a higher tumor mutational burden (TMB) (< 0.001) and lower tumor BRCA1/2 expression (< 0.001) in patients with mutations in the AKT pathway. These results are crucial for characterizing candidates for AKT pathway-targeted molecular therapies and conceptualizing optimal treatment strategies. Clinical trial registration: This study is an observational study and is therefore not registered with the clinical trials registration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseAdultAgedAged, 80 and overFemaleHumansMiddle AgedBiomarkers, TumorBone NeoplasmsBRCA1 ProteinBRCA2 ProteinCarcinoma, LobularClass I Phosphatidylinositol 3-KinasesJapanMutationPhosphatidylinositol 3-KinasesReceptors, ProgesteroneSignal Transduction

Stichwörter der Autor:innen

PI3K/AKT/PTEN alterationsAKT inhibitorsAKT pathway mutationsComprehensive genomic profilingMetastatic recurrent breast cancer

Substanzen

AKT1 protein, humanBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesPIK3CA protein, humanProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan. hiroshi.tada.a4@tohoku.ac.jp.
  • Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.

Zitieren

APA

Tada, H., Miyashita, M., Harada-Shoji, N., Ebata, A., Sato, M., Motonari, T., Yanagaki, M., Kon, T., Sakamoto, A., & Ishida, T. (2025). Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan. Breast Cancer. https://doi.org/10.1007/s12282-024-01639-6

Vancouver

Tada H, Miyashita M, Harada-Shoji N, Ebata A, Sato M, Motonari T, et al. Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan. Breast Cancer. 2025. doi:10.1007/s12282-024-01639-6

BibTeX
@article{Tada2025,
  author = {Tada, Hiroshi and Miyashita, Minoru and Harada-Shoji, Narumi and Ebata, Akiko and Sato, Miku and Motonari, Tokiwa and Yanagaki, Mika and Kon, Tomomi and Sakamoto, Aru and Ishida, Takanori},
  title = {Clinicopathogenomic analysis of PI3K/AKT/PTEN-altered luminal metastatic breast cancer in Japan},
  journal = {Breast Cancer},
  year = {2025},
  doi = {10.1007/s12282-024-01639-6}
}
Kostenlos starten →